Tier 2 — strong

Ornithine alpha-ketoglutarate improves wound healing in severe burn patients: a prospective randomized double-blind trial versus isonitrogenous controls

Coudray-Lucas C, Le Bever H, Cynober L, de Bandt JP, Carsin H
Critical Care Medicine 2000 28(6):1772-1776

Bibliography

PubMed
PMID 10890617
DOI
10.1097/00003246-200006000-00012
Funding
Non-U.S. government research support is indexed by PubMed; detailed funding is reported in the paper.
Competing interests
Historical trial; modern product-specific conflict reporting is limited.

Study snapshot

DesignProspective randomized double-blind controlled clinical trial.
ModelAdults with severe burns receiving early exclusive enteral nutrition.
Sample47 severe burn patients.
InterventionOrnithine alpha-ketoglutarate 20 g/day for 3 weeks versus an isonitrogenous soy-protein control.
Duration3 weeks supplementation with wound-healing follow-up.
EndpointsWound healing time; Protein catabolism; Nutritional markers; Tolerance; Antibiotic use

What the study showed, in plain terms

This randomized trial is a strong example of why different AKG salts must be kept separate.

Twenty grams per day of ornithine alpha-ketoglutarate shortened wound-healing time in severe burn patients and was reported as safe and well tolerated in that setting.

The intervention contains a large ornithine component and was used in hypercatabolic burn patients; its results cannot be attributed to Ca-AKG or used as longevity evidence.

Key findings

  • Wound-healing time was shorter with OKG than with the isonitrogenous control.
  • Markers suggested reduced protein hypercatabolism in less severely burned participants.
  • OKG was reported as safe and well tolerated in this three-week clinical context.

What this study can and cannot tell us

  • OKG is not Ca-AKG.
  • Severe-burn hypercatabolism is a highly specialized clinical setting.
  • Very high dose and short duration relative to longevity supplementation.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology